Total trials
395
Active
116
Phase 3
101
Total enrollment
1,141,498
Pipeline matrix
Showing 40 of 116 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Linvoseltamab | — | — | 14 | ||||
| Dupilumab | — | 47 | |||||
| Pozelimab | — | 17 | |||||
| Tocilizumab | — | — | — | 3 | |||
| ICS/LABA | — | — | — | — | — | 1 | |
| Cemiplimab | — | — | 45 | ||||
| Fianlimab | — | — | — | 11 | |||
| REGN7508 | — | — | — | 13 | |||
| Odronextamab | — | — | 10 | ||||
| Rituximab | — | — | — | — | — | 5 | |
| Cemdisiran | — | — | 11 | ||||
| REGN9933 | — | — | — | 8 | |||
| Mibavademab | — | — | — | — | 4 | ||
| Apixaban | — | — | — | — | 4 | ||
| Pemetrexed | — | — | — | 6 | |||
| Cisplatin | — | — | — | — | 5 | ||
| Paclitaxel | — | — | — | 5 | |||
| Carboplatin | — | — | — | 5 | |||
| Daratumumab | — | — | — | — | 4 | ||
| Dexamethasone | — | — | — | — | — | 4 | |
| Cyclophosphamide | — | — | — | — | 4 | ||
| Pomalidomide | — | — | — | — | 3 | ||
| Doxorubicin | — | — | — | — | — | 3 | |
| Vincristine | — | — | — | — | — | 3 | |
| Garetosmab | — | — | 6 | ||||
| Pembrolizumab | — | — | — | 6 | |||
| Bortezomib | — | — | — | — | 3 | ||
| Gemcitabine | — | — | — | — | 3 | ||
| Lenalidomide | — | — | — | — | 3 | ||
| Carfilzomib | — | — | — | — | 2 | ||
| Prednisone/Prednisolone | — | — | — | — | — | 2 | |
| REGN5713 | — | — | — | — | 4 | ||
| REGN5715 | — | — | — | — | 4 | ||
| Enoxaparin | — | — | — | — | 3 | ||
| Ravulizumab | — | — | — | — | — | 2 | |
| Eculizumab | — | — | — | — | — | 2 | |
| Rivaroxaban | — | — | — | — | 2 | ||
| Prednisone/Prenisolone | — | — | — | — | — | 1 | |
| Bendamustine | — | — | — | — | — | 1 | |
| relatlimab+nivolumab | — | — | — | — | — | 1 |
76 more active programs hidden
Next readouts
- 2025-03-31
- 2025-07-08
- 2025-07-17
- 2025-08-26
- 2026-02-23
- 2026-03-12
- 2026-04-20
- 2026-05-06
- 2026-05-18
- 2026-06-15
Top conditions
- Healthy Volunteers25
- Atopic Dermatitis18
- Healthy16
- Hypercholesterolemia12
- Healthy Volunteer10
- Melanoma10
- Paroxysmal Nocturnal Hemoglobinuria8
- COVID-197
Frequently asked questions about Regeneron Pharmaceuticals
- How many clinical trials does Regeneron Pharmaceuticals have on ClinicalTrials.gov?
- Regeneron Pharmaceuticals is listed as the lead sponsor on 395 clinical trials in ClinicalTrials.gov, 116 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Regeneron Pharmaceuticals's trials are in Phase 3?
- 101 of Regeneron Pharmaceuticals's trials are in Phase 3, spread across 116 active drug programs.
- What therapeutic areas does Regeneron Pharmaceuticals focus on?
- Regeneron Pharmaceuticals's most-studied conditions on ClinicalTrials.gov are Healthy Volunteers, Atopic Dermatitis, Healthy, Hypercholesterolemia, Healthy Volunteer.
- When are Regeneron Pharmaceuticals's next clinical trial readouts?
- Regeneron Pharmaceuticals has 10 upcoming primary-completion readouts tracked here; the soonest is “Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients”, expected around 2025-03-31.